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Abstract:  
The pace of change and, indeed, the sheer number of clinical ethics committees (not to be 
confused with research ethics committees) has accelerated during the COVID-19 pandemic. 
Committees were formed to support healthcare professionals and to operationalise, 
interpret and compensate for gaps in national and professional guidance.  But as the role of 
clinical ethics support becomes more prominent and visible, it becomes ever more 
important to address gaps in the support structure and misconceptions as to role and remit. 
The recent case of Great Ormond Street Hospital for Children NHS Foundation Trust v MX, FX 
and X ([2020] EWHC 1958 (Fam), [21]-[23] and [58]) has highlighted the importance of 
patient / family representation at clinical ethics committee meetings. The court viewed 
these meetings as making decisions about such treatment. We argue that this 
misunderstands the role of ethics support, with treatment decisions remaining with the 
clinical team and those providing their consent. The considered review by clinical ethics 
committees of the moral issues surrounding complex treatment decisions is not a matter of 
determining a single ethical course of action.  
In this article, we consider current legal understandings of clinical ethics committees, 





the various mechanisms of the inclusion of patients and their representatives in ethics 
meetings which is not standard in the UK.  
 
Introduction 
This paper aims to set out some of the misconceptions around clinical ethics support, 
focusing on the roles of clinical ethics committees and advisory groups (CECs). At a basic 
level, ethics support is the provision of assistance with regards to questions of morality in 
healthcare. It evolved as a system to aid healthcare professionals who were concerned 
about questions regarding the correct action in the care of their patients.1 Such questions 
have classically included resuscitation and end of life decisions, issues of competence and 
capacity and equity of fair access to treatments.  
Our focus is that of UK CECs. This is because the authors are familiar with their work, 
because the pandemic has exposed in a dramatic way the importance of their work but at 
the same time the ambiguity and uncertainty as to their proper role, and because of salient 
English law judgments as to who should attend meetings of CECs. This is not to say that we 
cannot learn from the experience of CECs from outside the UK. But our immediate focus is 
on those within the UK.   
Many CECs utilise existing ethical guidance and frameworks whilst deliberating complex and 
challenging situations,2 whether by regulatory bodies such as the GMC,3 Royal Colleges such 
as the RCPCH,4 or other bodies. Others have developed their own frameworks.5 
COVID-19 has stimulated a significant expansion in the number of CECs6 and provides both 





pandemic, professional bodies in England and Wales recognised the need for clinical ethics 
support regarding difficult choices which professional or national guidance did not cover. 
The Royal College of Physicians stated: 
Support with difficult decisions 
Medical ethicists (sometimes referred to as bioethicists) can help frontline staff with 
difficult decisions. Particularly where there is significant disagreement or a 
stakeholder might wish some form of external appeal other than a second opinion 
hospitals may wish to engage medical ethicists or form clinical ethics committees to 
help with such decisions.7 
The British Medical Association said: 
It is essential that employers take steps to provide appropriate support, including 
clinical ethics committee support and psychological support, to all health 
professionals working during the pandemic, many of whom may find working in the 
unfamiliar and strenuous conditions of a pandemic both practically difficult and 
morally and emotionally challenging.8 
The UK Clinical Ethics Network, established in 2001, provided guidance and support both for 
established committees and for NHS Trusts and private hospitals setting up new ones.9 
Questions of how CECs are constituted and trained are not considered here. They are 
important nevertheless, as is a recognition that membership of such committees is 
voluntary and unremunerated. 
Calling upon established or new CECs and services to operationalise and fill in gaps in 





immediately be addressed is admirable. It is essential that ethical dimensions of clinical 
decisions are given due consideration. But the ability of CECs as currently constituted to rise 
to the pandemic challenges is dependent on their function and form and the support they 
receive. Our aim is to articulate misconceptions, resolution of which would help to manage 
expectations and provide an impetus for improved support of clinical ethics services. 
 
What clinical ethics committees are not  
There are within the UK ethics committees other than CECs – those of the BMA and the 
Royal Colleges, for instance – and there are CECs in other jurisdictions outside the UK that 
differ in their form and function from the UK ones. This can lead to confusion as to the role 
and the resources of UK CECs. First, we should separate CECs and RECs (research ethics 
committees). RECs consider the approval of research trials; CECs consider the ethics of 
clinical treatment. Of course, there can be overlap, if, for instance, possible treatment 
would involve enrolment in a clinical trial. Nevertheless, CECs and RECs have distinct and 
distinguishable functions. 
Research ethics is managed and governed by a funded body, the Health Research Authority. 
One might assume that clinical ethics and research ethics have a similar provenance. Alas, 
clinical ethics lacks the well-funded governing authority and structure of research ethics.  
It is useful to contrast UK CECs with CECs in the United States and many European countries, 
which have a more formalised structure and support system. The UK Clinical Ethics Network 
aims to set standards and has provided core competencies,10 but not all UK CECs may avail 





A 2012 survey by Slowther et al. captured considerable variation in processes and form.11 
Recently, new infrastructures, such as regional groups of committees have been established 
in some areas, so as to share frameworks and improve consistency.  
 
Variation in function 
In 2001, Hendrick described three central functions of clinical ethics committees, ‘notably 
education, policy development and case review’.12 But there is variation as to how 
extensively these roles are embraced and understood, even by clinicians.13  A 2009 study 
revealed that whilst the number of committees was rising, there was a paucity of cases that 
some committees reviewed due, in part, to ‘low profile and lack of funding and support.’14 
In 2012, Slowther noted that some committees were not clear as to their role and 
function.15  
During the pandemic there has been emphasis on supporting clinicians through the 
development of frameworks16 and operational guidance;17 the newly constituted Devon 
committee is an excellent example of a newly formed CEC doing just this.  It is less clear how 
far CECs have engaged in case consultation in the pandemic.  
What is clear is that even before COVID-19, the role of some CECs was expanding. In 2020, 
the General Medical Council in its latest consent guidance mentioned for the first time the 
value in seeking advice from clinical ethics committees to resolve disagreements.18 The 
courts, meanwhile, appear to perceive CECs as an alternative dispute resolution mechanism 
that can avoid the need for the courts to become involved in the care of patients - which 





bioethics teams whose work extends beyond the committee in terms of supporting staff, 
patients and families going through very challenging periods; undertaking research into 
bioethical issues; and providing bioethics and law education, by relevant personnel where 
available, for staff.20 
We argue there is a nuanced role for ethics support, that goes beyond a binary contrast 
between decision-making and discussions to help clinicians and, depending on the process, 
patients and their relatives think through ethical issues. It is conceivable that ethics support, 
in whatever format, could either make non-binding recommendations or indicate some 
ethically proper choices or indeed identify ethically problematic options. 
 
Case review: adjudication or advice?  
One of the functions of CECs and services is to consult on difficult cases and provide advice. 
The advisory function is in stark contrast to the RECs we mentioned above. If RECs decide 
not to give ethical approval to a research project, it cannot go ahead in that form. So too, in 
other countries, there are examples of CECs which go beyond the giving of advice. In the 
USA case Re Quinlan,21 reliance was placed on ethics committee approval should the 
clinicians and family concur that treatment may be withdrawn. Some US states go further 
still and look to CECs to make decisions on behalf of patients lacking capacity to decide for 
themselves.22   
Given these examples and the lack of formal guidance and standing operating procedures 
for UK CECs, it is understandable that some might assume that they have a decision-making 





references CECs helping staff with difficult decisions and providing a route to ‘external 
appeal’, which potentially goes beyond mere advice. The courts seem to take a similar view. 
In Great Ormond Street Hospital for Children NHS Foundation Trust v MX, FX and X 23 (MX) 
which concerned a dispute around the end-of-life treatment of a nine-year-old child, Russell 
J was highly critical of perceived failures of the relevant clinical ethics committee to involve 
the family in their discussions. MX is a paediatric case which urges parental involvement in 
CEC discussions of their child's case. The impact of the case, however, is likely to extend 
beyond paediatrics.24 It may, for example, extend to family members of adults lacking 
capacity when complex decisions are being made about their care. Obviously, competent 
adults are entitled to give or to withhold consent to their own treatment. Evidently, they 
would have a say in what is done. Our sense is that the judgment has been taken up and 
understood in ways that suggest any patient with capacity, of whatever age, should be a 
party to the CEC discussions of cases involving their treatment.  
There are good reasons to involve patients or representatives, which we will come to 
shortly, but it is apparent that the judicial criticism gave weight to the CEC view as though it 
was decisional rather than advisory. Wilkinson and Dunn have said of the case: 
[S]ome of the suggestions made by the judge about how CECs should change how 
they work are potentially based on a mistaken conception of the function of a clinical 
ethics committee. And the broader idea that CECs should be conducting their 
business in a way that is more like a court room, with careful preparation and 
submission of evidence from both sides appears to be based on the idea that the aim 






Instead, they argue, CEC case reviews aim to ‘help the clinicians think through the ethical 
considerations and their options’. In the UK, the decision to offer medical treatment is that 
of the clinical team and the decision whether to consent usually rests with the patient 
unless there is a loss of capacity or the patient is a younger child. Neither is the role of ethics 
support services, whatever their structure. In the UK, CECs, despite previous and current 
suggestions, do not perform a quasi-judicial process that determines treatment decisions. 
Doyle clarified this and hoped it might encourage clinicians to seek ethics support by 
reassuring them of no loss of clinical decision making.26 It is, however, not clear if this 
perception has genuinely penetrated the judicial system or, indeed, the clinical sphere 
where, anecdotally, ethics referral can be perceived by clinicians as representing a failure in 
their relationship with patients or as a prelude to legal processes. 
Whilst CECs can and often do reach a consensus on a recommended course of action, they 
are set up to advise clinicians rather than to make clinical decisions. UK CECs are neither 
constituted nor capable of clinical decision-making. There is potential for more CECs to 
expand their role in alternative dispute resolution, but if the courts seek to utilise CECs as a 
mechanism to avoid the necessarily oppositional nature of the legal process, then CECs will 
need to be formalised, and representation considered including legal support for those 
involved. The distinction of ethics from healthcare mediations would need to be formalised.  
The number of contested cases in medicine, particularly for children, being played out in the 
public domain secondary to the change in confidentiality in the courts such as in the Family 
Division of the High Court has increased.27 Mediation has emerged as an option for tackling 
disagreements in healthcare,28 and family-centred care has entered the UK lexicon. Patients 





such as the management of end-of-life care.29 Bioethical mediation, which a CEC can 
sometimes facilitate,  has been shown to lead to the resolution of seemingly intractable 
disagreements without recourse to the courts.30 But there remains little standardisation, 
regulation or funding for this enterprise.  
The advantage of a more inquisitional rather than adversarial approach to determine the 
best interests of either children, or adults with incapacity is attractive but would require 
structure and funding, as well as the granting of legal authority to any new body to make 




A connected concern surrounds the relevance of patient representation. Patient and family 
representation can take many forms, from clinicians stating their interpretation of the 
patient viewpoint to patients/ family giving their opinion in ethics committee meetings. We 
have seen above that the court in MX seemed to ascribe the CEC a decision-making role as 
does the RCP COVID-19 guidance which says ‘a stakeholder might wish some form of 
external appeal other than a second opinion’. If the CEC was considered to be a decision-
making body, then in line with the Court of Appeal decision in Tracey31 the patient (or, if the 
patient lacks mental capacity, the family), may, depending on the nature of the decision, 
have a right to be consulted. The European Court of Human Rights has held that Article 8 of 
the European Convention on Human Rights requires a fair decision-making process ‘such as 





If the CEC role is advisory, as per the standard formulation of CECs, then there is still a 
strong case for patient representation, but the aim, in this case, would be to advise 
clinicians in light of the patient or families wishes, preferences and values rather than to 
give requisite protection to the patient’s article 8 interests through their involvement in the 
decision-making process.  The High Court in MX did not highlight the distinction between 
the two goals. There Russell J said: 
I consider that a lack of involvement by patients and / or their families is itself an 
issue of medical ethics and I am most surprised that there is not guidance in place to 
ensure their involvement and / or participation. … [W]here the quality of life of a 
disabled child with complex medical needs is a central issue, the involvement of 
parents in the clinical ethics committee process is essential.33 
If these words are used to improve patient participation in suitable cases then this is all for 
the good. With the ebbing of paternalism and emergence of a more consumerist model 
illustrated by choice of treating clinicians and the ready availability of private healthcare, the 
idea of a committee in a hospital discussing the ethical aspects of decision-making in the 
absence of the patient or their representatives seems archaic. Still, if patient representation 
is to be more widely advanced, the normative questions around the mechanisms for, extent 
of, and exceptions to patient involvement need to be clarified.34 
If, on the other hand, the judge’s dicta are interpreted as an endorsement of a CEC decision-
making process in which patients are represented, then for two principal reasons, we would 
argue that CECs, as currently constituted, are not capable of its delivery. First, as was 
acknowledged in MX,35 most committees discuss cases, issues or policies for the institution 





groups’ to make that clear. Ironically, the GOSH ethics committee at the heart of the 
criticism in MX for failing to represent the patient’s parents in ethics committee discussions 
is one of the few committees to invite parents and sometimes children to ethics meetings 
routinely. Second, in those CECs where support is provided, there is little overarching 
standardisation, governance or funding. There is a risk, therefore of inconsistency and 
injustice to patients. In MX, Russell J’s acknowledged:  
I was told that there is no protocol or definitive guidance for the constitution and 
conduct of Ethics Committees, particularly as to the involvement of patients or their 
families in the meetings and decisions.36  
There is potentially a role for CECs to engage more effectively in alternative dispute 
resolution (ADR) but for that to happen these deficiencies need to be addressed. 
An important point that is not a feature of recent court rulings is the large number of multi-
disciplinary clinical meetings that do feature the patient or their representatives. In complex 
paediatric cases, for example, daily meetings between the clinical team are frequent, as well 
as parent presence on ward rounds, though perhaps curtailed by recent COVID restrictions. 
Irrespective of this, the idea of a decisive ethics consultation occurring in the absence of 
prior discussion with a patient or their representatives is inaccurate. 
However, there are undoubtedly many important healthcare meetings that do not usually 
occur with either the patient or their representatives. These include surgical planning 
meetings, radiology meetings, pathology meetings, theatre meetings, discharge planning 
meetings – the list could continue. Is it the case that all such meetings that directly influence 





This then begs the question of what is meant by patient representation? Considering ethics 
meetings, this might consist of a right to attend; a routine invitation to meetings unless 
there is a clear – and communicated – reason for not doing so; a right to enter a written 
statement/video recording. There is also the consideration about whether attendance is for 
all or only for a specific part of any meeting, and of whether patients/representative are 
notified of the meeting and/or notification of outcome.  
One new issue that has been highlighted by COVID-19 is the role of video-conferencing. 
Patients and their relatives can now readily attend conferences about their care from their 
bedside or home, given the availability of adequate technology. What is, as yet, unclear is 
whether the nature of ethics or indeed other complex meetings, either with or without 
patients, are fundamentally changed by taking place in this novel way. Could professionals 
or patients/their families be intimidated or emboldened by this environment. Are none 
verbal communications important or unnecessary? 
The courts often do request information about ethics committee involvement in contested 
cases and receive it in the form of minutes, a meeting report or oral testimony. We are 
unaware of ethics committee members giving evidence in that role. Overall, this means that 
the courts receive what is often quite complex and nuanced ethical deliberation second 








Pre-COVID, CECs were undergoing a transformation in response to a growing appreciation of 
their value both to support clinicians to make ethical decisions and to help to resolve 
disputes. We would support a role for ethics services in any UK ADR process, in conjunction 
with pastoral, mediation and legal expertise. This would require representation for patients 
and their relatives in a manner that current ethics support does not widely support.  
The COVID-19 pandemic has highlighted the lack of formal ethics processes in most UK 
hospitals and by extension social care facilities, at a time of unprecedented need for such 
support. Some clinical ethics committees have been hastily assembled, with little 
standardisation or legal clarity on their operation.37 Individual and regional groups have 
formed, but there is a lack of research as to how COVID-19 has impacted on composition 
and function of CECs and on the decision-making frameworks utilised.  
We welcome recognition by the BMA and RCP that ethical support is pertinent to difficult 
clinical decisions. Expectations of CECs are high. The volunteers who rise to the challenges 
of COVID and non-pandemic related dilemmas such as end-of-life disputes that are subject 
to ever-increasing levels of, often inaccurate, media exposure38 are deserving of praise and 
gratitude. We have referred to some assumptions and misconceptions about the role and 
function of ethics support, giving examples relating to our courts, professional bodies and 
clinicians. There is a danger that misconceptions could lead to unmet expectations. One 
option is to bring expectations into line with practice to maintain the flexibility and diversity 
of the current ethical support system. The other option is to bring the system in line with 
expectations through greater standardisation, governance and funding, albeit after a more 
fundamental reconsideration of the very function of ethics support. The question then is 
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